JP2005501532A5 - - Google Patents

Download PDF

Info

Publication number
JP2005501532A5
JP2005501532A5 JP2003506300A JP2003506300A JP2005501532A5 JP 2005501532 A5 JP2005501532 A5 JP 2005501532A5 JP 2003506300 A JP2003506300 A JP 2003506300A JP 2003506300 A JP2003506300 A JP 2003506300A JP 2005501532 A5 JP2005501532 A5 JP 2005501532A5
Authority
JP
Japan
Prior art keywords
antigens
examples
derived
pathogens
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003506300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501532A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/017374 external-priority patent/WO2002102828A2/en
Publication of JP2005501532A publication Critical patent/JP2005501532A/ja
Publication of JP2005501532A5 publication Critical patent/JP2005501532A5/ja
Pending legal-status Critical Current

Links

JP2003506300A 2001-06-01 2002-05-31 キメラフラビウイルスベクター Pending JP2005501532A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29526501P 2001-06-01 2001-06-01
PCT/US2002/017374 WO2002102828A2 (en) 2001-06-01 2002-05-31 Chimeric flavivirus vectors

Publications (2)

Publication Number Publication Date
JP2005501532A JP2005501532A (ja) 2005-01-20
JP2005501532A5 true JP2005501532A5 (enExample) 2010-03-25

Family

ID=23136958

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003506300A Pending JP2005501532A (ja) 2001-06-01 2002-05-31 キメラフラビウイルスベクター

Country Status (11)

Country Link
US (2) US7569383B2 (enExample)
EP (1) EP1401859B1 (enExample)
JP (1) JP2005501532A (enExample)
KR (1) KR100921592B1 (enExample)
CN (1) CN1551782A (enExample)
AU (1) AU2002322026B2 (enExample)
BR (1) BR0210907A (enExample)
CA (1) CA2448971C (enExample)
ES (1) ES2439724T3 (enExample)
PL (1) PL371187A1 (enExample)
WO (1) WO2002102828A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
EP1401859B1 (en) 2001-06-01 2013-08-07 Sanofi Pasteur Biologics Co. Chimeric flavivirus vectors
JP2005519639A (ja) 2002-01-15 2005-07-07 アカンビス インコーポレーティッド フラビウイルスワクチン
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
KR101150584B1 (ko) 2002-11-15 2012-06-27 사노피 파스테르 바이오로직스 씨오 웨스트 나일 바이러스 백신
JP2009543554A (ja) * 2006-07-14 2009-12-10 サノフィ パスツール バイオロジクス カンパニー ベクターウイルスタンパク質への外来免疫決定基の直接トランスポゾン媒介挿入による組換え型ウイルスワクチンの構築
EP2069483A4 (en) * 2006-09-29 2010-10-27 Sanofi Pasteur Biologics Co RECOMBINANT RHINOVIRUS VECTORS
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
CN101808657A (zh) 2006-11-07 2010-08-18 赛诺菲巴斯德生物制剂公司 冻干法稳定疫苗
US8591916B2 (en) 2007-01-31 2013-11-26 Sanofi Pasteur Biologics, Llc Flavivirus vaccine vector against influenza virus
WO2009030872A1 (en) * 2007-09-07 2009-03-12 Mats Axel Atterdag Persson Materials and methods for the treatment of hepatitis c
CN105944095B (zh) 2008-03-05 2021-04-02 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
WO2009114207A2 (en) * 2008-03-14 2009-09-17 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccines and vaccine vectors
BRPI0909119A2 (pt) * 2008-03-27 2017-06-13 Sanofi Pasteur Biologics Co vetores recombinantes do rinovírus
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
CA2755257A1 (en) * 2009-03-16 2010-09-23 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccine vectors against respiratory syncytial virus
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
PH12014500911A1 (en) * 2011-10-25 2014-06-09 Florida Gulf Coast Univ Board Of Trustees Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes
KR20150036592A (ko) 2012-07-24 2015-04-07 사노피 파스퇴르 백신 조성물
US20150265695A1 (en) 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
CN103352029A (zh) * 2013-07-29 2013-10-16 中国人民解放军军事医学科学院微生物流行病研究所 一种乙脑/森林脑炎嵌合病毒及其应用
EP3158061B1 (en) * 2014-06-20 2019-08-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Chimeric west nile/dengue viruses and methods of use
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
BE1024160B9 (fr) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
CN110506060B (zh) 2017-03-30 2024-05-07 昆士兰大学 嵌合分子及其用途
WO2019040994A1 (en) 2017-09-01 2019-03-07 The Australian National University IMMUNOREGULATOR MOLECULES AND USES THEREOF
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
AU2020273263A1 (en) * 2019-04-10 2021-12-02 Katholieke Universiteit Leuven Chimeric Zika-Japanese encephalitis virus
CN111798712B (zh) * 2020-07-15 2021-10-29 周晓庆 噬菌体侵染细菌3d智能模拟方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
EP0872553B1 (en) 1991-09-19 2000-11-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES Chimeric and/or growth-restricted flaviviruses
US6136561A (en) 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
ES2345614T3 (es) 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6416763B1 (en) 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
JP2003507048A (ja) * 1999-08-20 2003-02-25 ウイスコンシン アラムナイ リサーチ フオンデーシヨン β−グルクロニダーゼのアスパラギン酸およびリンゴ酸阻害
AU1813901A (en) 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
EP1401859B1 (en) * 2001-06-01 2013-08-07 Sanofi Pasteur Biologics Co. Chimeric flavivirus vectors
US6682883B1 (en) 2001-07-19 2004-01-27 Acambis, Inc. Diagnosis of flavivirus infection
KR20120016315A (ko) 2001-10-19 2012-02-23 사노피 파스테르 바이오로직스 씨오 동물의 플라비바이러스 감염 예방 및 치료 방법
JP2005519639A (ja) 2002-01-15 2005-07-07 アカンビス インコーポレーティッド フラビウイルスワクチン
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
AU2003239932A1 (en) 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
KR101150584B1 (ko) 2002-11-15 2012-06-27 사노피 파스테르 바이오로직스 씨오 웨스트 나일 바이러스 백신
US7189403B2 (en) 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
WO2005040390A1 (en) 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. A recombinant vaccine using yellow fever virus as vector
WO2005049815A1 (en) 2003-11-21 2005-06-02 K.U.Leuven Research & Development Flavivirus replication
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
US8124398B2 (en) 2005-04-24 2012-02-28 Sanofi Pasteur Biologics Co. Recombinant flavivirus vaccines
BRPI0504945B8 (pt) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.

Similar Documents

Publication Publication Date Title
UA85536C2 (en) Viral antigens
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
JP2004524889A5 (enExample)
EP2275131A3 (en) HCV Vaccines
ATE275631T1 (de) Rekombinanter venezolanische-equine- pferdeenzephalitis-virusimpstoff
JP2004538039A5 (enExample)
JP2005502322A5 (enExample)
EP1741782A3 (en) Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
JP2002524024A5 (enExample)
IL202249A (en) Nucleic Acids Encoders Human Immunodeficiency Strange Type 1 (HIV – 1) Group M Consensus Envelope Glycoproteins
ATE257175T1 (de) Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
EP2290091A3 (en) Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
JP2003160581A5 (enExample)
EP2368576A3 (en) Functionally reconstituted viral membranes containing adjuvant
JP2005511495A5 (enExample)
ATE455791T1 (de) T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon
DE60330966D1 (de) Rekombinante vesicular stomatitis viren als impstoff gegen virale hämorrhagische fieber
DE60042816D1 (de) T-helferzellen-epitope
EP1399481A4 (en) RECOMBINANT ANTIBODIES TO INFECTIOUS BURSAL DISEASE VIRUS (IBDV)
JP2005534326A5 (enExample)
JP2003514090A5 (enExample)
ATE437656T1 (de) Impfstoff gegen das maul- und klauensäure-virus
JP2007516701A5 (enExample)
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
AU2002952524A0 (en) Epstein barr virus peptide epitopes